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Abstract 
OBJECTIVE: To report a case of renal arterial embolisation (RAE) in unresectable renal tumour before 
nephrectomy. 
CASE REPORT: On presentation, the clinical features of this patient, including medical history, signs and 
symptoms, imaging examinations were recorded. After diagnosis and initial treatment, the result and 
histopathological examination were performed and discussed. We performed RAE in the unresectable renal 
tumour in the 28-year-old male that was complaining a palpable pain right flank mass and intermittent hematuria 
that had been observed five months earlier. A month after RAE, the tumour shrinks and become resectable. The 
parameter used was tumour volume, propulsion and component, with subjective value VAS, hematuria symptom 
and Quality Of Life Score EORTC-QLQ C30. The next step we performed nephrectomy with histopathology 
results in Clear Cell Renal Carcinoma (CCRC). 
CONCLUSION: RAE is an effective therapeutic and adjuvant tool because it facilitates the dissection of 
unresectable large renal tumours and tumours with extensive involvement around the renal hilum; it leading to 
lower overall morbidity. However, the lack of randomised prospective studies is the primary reason that RAE is 
not used often before surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Renal cell carcinoma (RCC) constitutes 
approximately 90–95% of all kidney neoplasms, and 
25–30% of all patients had metastatic disease upon its 
diagnosis. The incidence rates are high in the Czech 
Republic, and low in much of Africa and South-east 
Asia country [1]. In Indonesia, renal cell carcinoma 
was ranked 18
th
 in both sexes for the overall 
incidence. It occurs in 1.4-1.8 cases per 100.000 
populations [2].  
Renal arterial embolisation (RAE) has been 
proven safe and effective in managing renal cancer 
for several decades of experience. This procedure 
was first performed in 1973 by Almgard [3]. Since 
then, the procedure has developed due to advances 
in technology and instrumentation. The main 
indication of RAE is preoperative infarction of renal 
cancer before nephrectomy. It can also be done as 
palliation therapy for unresectable renal cancer, 
symptomatic hematuria, and treatment of 
angiomyolipomas (AMLs), treatment for vascular 
malformations, correcting of complications following 
renal transplantation and treatment for patients who 
are poor for surgical candidates [4].  
In our country, systemic therapy for renal 
cancer has not been covered by the national health 
insurance. Therefore, RAE can be a promising 
treatment option for renal cancer patients. The long-
term outcome of RAE, however, remains unknown. In 
this case report, we described a patient with RCC who 
underwent RAE as preoperative infarction of renal 
cancer before nephrectomy. 
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Case presentation 
 
Previously 28-year-old man was admitted to 
the hospital with the chief complain of a palpable 
painful right flank mass. There was a history of 
intermittent hematuria that had been observed five 
months earlier. He also had a history of nausea and 
weight loss. The patient had no family history of a 
renal tumour. On physical examination, the patient 
looked pale. There was a mobile palpable mass in the 
right flank across the midline. The diameter was 
estimated to be more than 25cm. Urinalysis 
examination showed microscopic hematuria. We also 
performed upper lower abdominal CT scan for this 
patient who showed a huge mass in the right Kidney 
(Figure 1 and 2).  
 
Figure 1: Abdominal CT Scan in coronal plane showed the tumour 
extent (1A) before RAE was performed, (1B) after 1
st
 RAE 
performed, (C) after 2
nd
 RAE performed, it shows that a tumour 
gradually decreased in size according to coronal view 
 
We diagnosed this patient with unresectable 
Renal Tumor with grading T4BN1M0, with the 
extension of the lymph node in paracaval and 
interaortocaval without long distance metastatic, the 
tumour pressing through the midline and suspected 
compelling the aorta and inferior vena cava.  
 
Figure 2: Abdominal CT Scan in axial plane showed the tumour 
extent (2A) before RAE performed, (2B) after 1
st
 RAE performed, 
(C) after 2
nd
 RAE performed, it shows that a tumour gradually 
decreased in size according to axial view 
 
After the patient had signed the written 
informed consent, the patient was scheduled for the 
procedure. Under local anaesthesia, we performed 
arterial vascular access by inserting a vascular sheath 
(5 Fr-Simmon-shaped catheters) via the right common 
femoral artery (CFA). An aortography was then 
performed with a ﬂush catheter which placed slightly 
superior to the expected origin of the renal arteries. 
Aortography is beneficial to evaluate renal arteries 
vascularisation and to determine, if present, the 
accessory renal arteries. Supplying tumour artery was 
selectively catheterised and embolize using polyvinyl 
alcohol (PVA). PVA 300-500 µm were exposed to the 
target using occlusion balloon catheter delivery 
technique. 
Table 1: Tumor evaluation parameter 
No. Parameter Before After RAE  1
st 
After RAE 2
nd 
1 Tumor volume 2800 cc 2300cc 1700cc 
2 Tumour aggravation Across the midline, 
compelling the 
aorta and vena 
cava 
Across the midline 
Compelling the 
aorta and vena 
cava 
Not crossing the 
midline 
and compelling the 
aorta and vena 
cava 
3 Tumor component Cystic 
HU: 0-45 
Necrotic (+) 
HU: 0-191 
Necrotic (+) 
HU: 0-300 
4 VAS 6-8 2-3 0 
5 Hematuria (+) (-) (-) 
6 Quality of Life score 
measured by EORTC-
QLQ C30 
100 86 70 
Note: HU = Hounsfield unit; VAS = Visual Analogue Score; EORTC-QLQ = European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire. 
 
After the procedure was completed, the 
patient again undergoing aortography to evaluate the 
outcome of the procedure. In this patient, we 
performed RAE two times with further evaluation. 
Table 1, Figure 3 and Figure 4 show the tumour 
response after the first and second procedure. The 
parameter used was tumour volume, tumour 
aggravation and tumour component from the 
abdominal CT Scan, visual analogue score (VAS), the 
presence of hematuria and the patient quality of life 
measured by EORTC-QLQ C30.  
 
Figure 3: Abdominal CT Scan with vascular description in the 3D 
plane shows the vascular profile (3A) before RAE was performed, 
(3B) after 1
st
 RAE, main renal artery was successfully blocked but 
remaining artery in inferior mesenteric and extrarenal collateral 
vascular supply cannot be blocked by RAE, (3C) after 2
nd
 RAE was 
performed, it shows that tumor vascular supply in mesenteric 
inferior and collateral artery had minimized 
 
After a month of evaluation, we performed 
nephrectomy with chevron incision in this patient. 
During the procedure, we found only small adhesion 
in anterior and inferior with the ileum and no adhesion 
in solid organ (Fig. 5). The total blood loss is 500 cc. 
No intraoperative transfusion is needed. The surgical 
specimen was then delivered to the pathology 
department. Histological analysis revealed a Clear 
Cell Renal Carcinoma (CRCC) (Fig. 6). 
 
 
Discussion 
 
CRCC is the most common and aggressive 
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RCC subtype with the highest rates of local invasion-
metastasis and mortality. It constitutes 70–80% of all 
renal cancers, these tumours are commonly yellow 
when they are bivalve and are highly vascular on 
microscopic examination. The type of CRCC can be a 
clear cell, granular cell or mixed type. In general, 
patients with clear cell RCC have a worse prognosis 
compared with papillary or chromophobe RCC, even 
after stratification for stage and grade [5] [6].  
 
Figure 4: Fluoroscopy result shows (4A) first embolisation, (4B) 
second embolisation 
 
RAE was first popularised by Almgard et al. In 
the 1970s, Almgard et al. performed occlusion 
treatment in 19 patients with three different diagnoses. 
Eleven cases were a large metastasising tumour, four 
cases were a large tumour without metastases, and 
the other four cases were troublesome haematuria. 
The method used was the same method that had 
been tested on animals two years earlier [3].  
 
Figure 5: Tumor description after nephrectomy (5A) tumor with size 
25cm x15 cm x 6 cm, (5B) tumor with midline dissection 
 
At the first time, RAE was primarily used to 
treat unresectable symptomatic renal cancer. 
Currently, the indications for RAE have considerably 
expanded including renal trauma, renal tumours, 
iatrogenic complications, and medical renal disease 
[7] [8]. The advantages of RAE in the preoperative 
setting include a decrease in perioperative blood loss, 
the creation of a tissue plane of oedema, facilitating 
dissection, and reduction in tumour bulk including the 
extent of vascular thrombus [4].  
Before performing the procedure, it is 
important to have sufficient knowledge of anatomy 
and its variations of renal vascularisation. Normally, a 
single renal artery arises from each left and right 
inferior side of the abdominal aorta at the level of the 
L1–L2 interspace. The main renal arteries branch into 
anterior and posterior divisions then continue as 
segmental, lobar, interlobar, and arcuate arteries. 
There are anatomical variations in more than 30% 
people, like the early division of the main renal 
arteries or extrarenal arteries further subdivided into 
accessory (hilar) or aberrant (polar) entry into the 
kidney [9].
  
 
Figure 6: a) cRCC Histopathology is shown in a microscope with 20 
x larger; b) The Blue Arrow Showed cRCC Histopathology in 40 x 
larger with clear arrow showed clear cytoplasmic with nuclei with 
irregular contour with Fuhrman Classification grade III 
 
The common femoral artery (CFA) had been 
increasingly used as the preferred access site for 
renal arterial embolisation. The vascular access is 
generally performed using the 18 or 19-gauge 
puncture needles with the modified Seldinger 
puncture technique. In some cases where the access 
cannot be done through the CFA, the axillary or 
brachial arteries can be used as an alternative. The 5-
French sheath used mostly to minimise the risk of 
access site bleeding. For selective embolisation of the 
renal arteries, some catheter can be used, including 
an RC-2 shaped catheter, SOS-shaped catheter, 
Cobra or Simmons-shaped catheter. There are some 
conditions that require special consideration for the 
sake of patient safety including atherosclerosis, 
abdominal aortic aneurysm, narrowing iliac artery, 
renal artery stenosis, or mass effect of a 
retroperitoneal tumour. In this patient, there are no 
such conditions [10] [11].  
Renal tumours are typically hypervascular 
and often with extrarenal arterial involvement. 
Therefore, the alternative agent that can reach the 
small vessel and capillary bed occlusion is needed. In 
the literature, for kidney cancer cases, there is no 
specific agent recommended to have a better 
effectivity than others. In our institution, we use 
polyvinyl alcohol as embolant agent [12] [13]. Foam 
forms of PVA were first used in the 1970’s [14]. The 
small amount of PVA for tumour embolisation may 
result in significant tissue ischemia. PVA is delivered 
through the catheter in suspension form. PVA causes 
direct mechanical obstruction and induces a foreign 
body type reaction with the permeation of the particles 
by granulation tissue. Over time this reaction 
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subsides, and months to years later, the vessel may 
recanalise. Although PVA is considered to be a 
permanent agent, it will recanalise over time [15].  
Although this procedure is less invasive than 
open surgery, RAE has its share of complications, 
related to the procedure and the underlying pathology. 
The most common complication is a postembolization 
syndrome that affects over 90% of patients. It is 
defined as fever, mild flank pain, nausea, vomiting, 
paralytic ileus, and leucocytosis for one until three 
days after the procedure. Supportive treatment is 
often enough to resolve the symptoms. The other 
complications such as infection and coil migration are 
rare [16]. 
There are some limitations to this case report. 
The patient needs to be evaluated for a longer period. 
1-year-follow-up is recommended to investigate any 
side effect of the procedure, relapse, or another 
progression. More subjects undergoing RAE should 
be investigated to obtain more significant outcomes. 
In conclusion, RAE is an effective therapeutic 
and adjuvant tool because it facilitates the dissection 
of unresectable large renal tumour and tumour with 
extensive involvement in the renal hilum. It leads to 
lower overall morbidity and can also be a neoadjuvant 
treatment before radical nephrectomy. However, the 
lack of randomised prospective studies is the primary 
reason why RAE is still rarely used as premedication 
before surgery. 
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